Bookmarks
Cardiovascular disease (CVD)-COVID-UK / COVID-IMPACT
Description
Trusted Research Environment for CVD-COVID-UK (Wales + Census)
Dataset population size: 3,107,493
Health and disease, Registry, Treatments/Interventions, Measurements/Tests, Socioeconomic, Lifestyle, Environment and energy
Trusted Research Environment for CVD-COVID-UK (Scotland)
Dataset population size: 5,411,922
Health and disease, Registry, Treatments/Interventions, Measurements/Tests, Socioeconomic, Lifestyle, Environment and energy
Trusted Research Environment for CVD-COVID-UK (Wales)
Dataset population size: 3,107,492
Health and disease, Registry, Treatments/Interventions, Measurements/Tests, Socioeconomic, Lifestyle, Environment and energy
Secure Data Environment for CVD-COVID-UK / COVID-IMPACT (England)
Dataset population size: 57,000,000
Health and disease, Registry, Treatments/Interventions, Measurements/Tests, Socioeconomic, Lifestyle, Environment and energy
Welsh Longitudinal General Practice Dataset (WLGP) - Welsh Primary Care
Dataset population size: 5,917,115
Health and disease
CCU002: SARS-CoV-2 infection and vaccination and the risk of vascular events
University of Edinburgh
CCU004: COVID and Cardiovascular Disease Risk Prediction
University of Cambridge
CCU005: Data management and analysis methods
University of Cambridge
Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort.
Handy A, Banerjee A, Wood AM, Dale C, Sudlow CLM, Tomlinson C, Bean D, Thygesen JH, Mizani MA, Katsoulis M, Takhar R, Hollings S, Denaxas S, Walker V, Dobson R, Sofat R, CVD-COVID-UK Consortium.
2022
COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records.
Thygesen JH, Tomlinson C, Hollings S, Mizani MA, Handy A, Akbari A, Banerjee A, Cooper J, Lai AG, Li K, Mateen BA, Sattar N, Sofat R, Torralbo A, Wu H, Wood A, Sterne JAC, Pagel C, Whiteley WN, Sudlow C, Hemingway H, Denaxas S, Longitudinal Health and Wellbeing COVID-19 National Core Study and the CVD-COVID-UK/COVID-IMPACT Consortium.
2022
Risk of myocarditis and pericarditis following BNT162b2 and ChAdOx1 COVID-19 vaccinations
Ip S, Torabi F, Denaxas S, Akbari A, Abbasizanjani H, Knight R, Cooper J, Denholm R, Keene S, Bolton T, Hollings S, Omigie E, North T, Suseeladevi AK, Angelantonio ED, Khunti K, Sterne JAC, Sudlow C, Whiteley W, Wood A, Walker V.
2022
Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study.
Mizani MA, Dashtban A, Pasea L, Lai AG, Thygesen J, Tomlinson C, Handy A, Mamza JB, Morris T, Khalid S, Zaccardi F, Macleod MJ, Torabi F, Canoy D, Akbari A, Berry C, Bolton T, Nolan J, Khunti K, Denaxas S, Hemingway H, Sudlow C, Banerjee A, CVD-COVID-UK Consortium.
2023
A nationwide deep learning pipeline to predict stroke and COVID-19 death in atrial fibrillation
Handy A, Wood A, Sudlow C, Tomlinson C, Kee F, Thygesen JH, Mamouei M, Sofat R, Dobson R, Ip S, Denaxas S.
2021
A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease.
Dashtban A, Mizani MA, Denaxas S, Nitsch D, Quint J, Corbett R, Mamza JB, Morris T, Mamas M, Lawlor DA, Khunti K, CVD-COVID-UK Consortium, Sudlow C, Hemingway H, Banerjee A.
2022